Zhejiang Medicine Co., Ltd. (SHA:600216)
China
· Delayed Price · Currency is CNY 13.39
-0.27 (-1.98%)
Apr 28, 2025, 3:00 PM CST
Zhejiang Medicine Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 1,320 | 1,020 | 429.64 | 539.57 | 1,045 | 717.4 | Upgrade
|
| Depreciation & Amortization | 723.01 | 723.01 | 659.38 | 681.6 | 587.57 | 503.81 | Upgrade
|
| Other Amortization | 3.54 | 3.54 | 68.24 | 3.75 | 0.08 | 1.12 | Upgrade
|
| Loss (Gain) From Sale of Assets | -3.09 | -3.09 | -330.16 | -3.31 | 7.95 | 23.48 | Upgrade
|
| Asset Writedown & Restructuring Costs | 293.74 | 293.74 | 15.81 | 12.8 | 46.19 | 9.85 | Upgrade
|
| Loss (Gain) From Sale of Investments | 8.07 | 8.07 | 28.59 | 56.51 | -93.54 | -150.22 | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | 0.15 | -2.94 | 10.63 | -16.47 | Upgrade
|
| Other Operating Activities | -9.4 | 8.24 | -76.42 | -73.46 | 58.32 | 173.37 | Upgrade
|
| Change in Accounts Receivable | -759.44 | -759.44 | -29.42 | -161.98 | -402.19 | 76.5 | Upgrade
|
| Change in Inventory | -347.26 | -347.26 | -263.73 | -330.7 | -760.57 | -215.11 | Upgrade
|
| Change in Accounts Payable | 305.37 | 305.37 | 101.7 | -218.05 | 577.5 | 154.68 | Upgrade
|
| Change in Other Net Operating Assets | 13.69 | 13.69 | 37.47 | 33.35 | 42.24 | - | Upgrade
|
| Operating Cash Flow | 1,505 | 1,223 | 634.31 | 520.6 | 1,137 | 1,257 | Upgrade
|
| Operating Cash Flow Growth | 136.08% | 92.86% | 21.84% | -54.20% | -9.55% | 180.99% | Upgrade
|
| Capital Expenditures | -658.78 | -689.14 | -796.87 | -975.99 | -939.6 | -535.35 | Upgrade
|
| Sale of Property, Plant & Equipment | 6.57 | 200.49 | 174.48 | 7.2 | 6.97 | 27.43 | Upgrade
|
| Cash Acquisitions | - | - | - | - | -140.73 | - | Upgrade
|
| Divestitures | - | - | - | 9.12 | - | -1.6 | Upgrade
|
| Investment in Securities | -28.66 | -26.39 | 102.02 | -40.46 | 39.13 | 300.32 | Upgrade
|
| Other Investing Activities | 31.16 | 41.54 | 0.78 | 1.75 | 1.98 | 6.64 | Upgrade
|
| Investing Cash Flow | -649.7 | -473.5 | -518.59 | -971.15 | -983.69 | -237.72 | Upgrade
|
| Long-Term Debt Issued | - | 520 | 600 | 660.74 | 580 | 1,400 | Upgrade
|
| Long-Term Debt Repaid | - | -573 | -600.34 | -726.21 | -700.43 | -1,098 | Upgrade
|
| Net Debt Issued (Repaid) | -55 | -53 | -0.34 | -65.47 | -120.43 | 302.04 | Upgrade
|
| Issuance of Common Stock | - | - | - | 59.95 | - | - | Upgrade
|
| Repurchase of Common Stock | - | - | -1.29 | - | - | - | Upgrade
|
| Common Dividends Paid | -169.35 | -170.31 | -191.91 | -351.09 | -260.06 | -1,006 | Upgrade
|
| Other Financing Activities | -32.01 | -32.01 | 52.12 | 400.53 | 450.25 | 76.73 | Upgrade
|
| Financing Cash Flow | -256.37 | -255.32 | -141.43 | 43.91 | 69.75 | -627.47 | Upgrade
|
| Foreign Exchange Rate Adjustments | 34.05 | 11.27 | 47.64 | 76.01 | -79.84 | -42.7 | Upgrade
|
| Net Cash Flow | 633.08 | 505.75 | 21.93 | -330.62 | 142.88 | 348.82 | Upgrade
|
| Free Cash Flow | 846.32 | 534.15 | -162.56 | -455.39 | 197.05 | 721.37 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | -72.68% | - | Upgrade
|
| Free Cash Flow Margin | 9.02% | 5.70% | -2.09% | -5.61% | 2.16% | 9.84% | Upgrade
|
| Free Cash Flow Per Share | 0.89 | 0.56 | -0.17 | -0.47 | 0.20 | 0.75 | Upgrade
|
| Cash Interest Paid | - | - | 0.4 | 0.4 | - | - | Upgrade
|
| Cash Income Tax Paid | 335.41 | 352.56 | 163.05 | 344.56 | 384.41 | 307.7 | Upgrade
|
| Levered Free Cash Flow | 519.37 | 584.85 | -60.17 | -899.57 | 1,076 | 613.73 | Upgrade
|
| Unlevered Free Cash Flow | 519.37 | 584.85 | -42.46 | -878.88 | 1,100 | 642.65 | Upgrade
|
| Change in Net Working Capital | 682.75 | 395.19 | -0.67 | 927.62 | -684.91 | -185.99 | Upgrade
|
Updated Oct 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.